How is Depo‑Provera (medroxyprogesterone acetate) injection administered and what are its contraindications, side effects, and follow‑up recommendations?

Depo-Provera Injection Administration and Clinical Guidance

Depo-Provera (medroxyprogesterone acetate) is administered as 150 mg by deep intramuscular injection into the gluteal or deltoid muscle every 13 weeks, with the critical limitation that it should not be used for longer than 2 years unless other contraceptive options are inadequate due to significant bone mineral density loss. 1

Administration Protocol

Dosing and Technique

• Dose: 150 mg every 3 months (13 weeks) 1
• Route: Deep intramuscular (IM) injection using strict aseptic technique
• Sites: Gluteal or deltoid muscle, rotating sites with each injection
• Preparation: Vigorously shake vial or prefilled syringe immediately before use to ensure uniform suspension 1
• Needle consideration: Assess body habitus before each injection to determine if a longer needle is needed, particularly for gluteal injections to avoid inadvertent subcutaneous administration 1

Timing of First Injection

• During menstrual cycle: ONLY during first 5 days of normal menstrual period 1
• Postpartum (non-breastfeeding): Within first 5 days postpartum 1
• Postpartum (exclusively breastfeeding): During or after the sixth postpartum week 1

Reinjection Window

• Standard interval: Every 13 weeks
• Grace period: Can be given up to 2 weeks late (15 weeks from last injection) without requiring additional contraceptive protection 2
• If >13 weeks: Confirm patient is not pregnant before administering 1

Absolute Contraindications

The following conditions prohibit use of Depo-Provera 1:

1. Thromboembolic disease: Active thrombophlebitis, current or history of thromboembolic disorders, or cerebrovascular disease
2. Breast cancer: Known or suspected malignancy of breast
3. Hypersensitivity: Known allergy to medroxyprogesterone acetate or any ingredient
4. Liver disease: Significant hepatic impairment
5. Undiagnosed vaginal bleeding: Must be evaluated before initiation

Critical Warnings and Side Effects

Bone Mineral Density Loss (Black Box Warning)

• Most significant concern: Progressive bone loss that increases with duration of use and may not be completely reversible 1
• Adolescent risk: Unknown if use during adolescence/early adulthood (critical bone accretion period) reduces peak bone mass and increases future osteoporotic fracture risk 1
• Duration limit: Not recommended for >2 years unless other options inadequate 1

Common Side Effects

• Menstrual changes: Most common issue—expect irregular bleeding, spotting, or amenorrhea (often progresses to amenorrhea with continued use) 3
• Weight gain: Frequently reported 3
• Delayed return to fertility: MPA can be detected in serum for up to 9 months after single injection; ovulation resumes when levels fall below 0.1 ng/mL 4

Management of Bleeding Irregularities

For patients desiring treatment while continuing method 3:

• NSAIDs: 5-7 days for spotting, light bleeding, or heavy/prolonged bleeding
• Explore patient goals and provide reassurance
• If patient desires discontinuation, offer counseling on alternative methods

Emerging Safety Concern

Recent 2025 data shows increased meningioma risk with depot medroxyprogesterone acetate (relative risk 2.43), particularly with >4 years exposure or initiation after age 31, though the number needed to harm is high (1,152 patients) 5. This represents new evidence that should inform counseling, especially for long-term users.

Follow-Up Recommendations

Routine Monitoring

• No routine follow-up required 2
• Patient should be encouraged to contact provider at any time to:
  1. Discuss side effects or problems
  2. Request method change (including switching to provider-administered DMPA)
  3. Ask questions about reinjection 2

Reinjection Schedule

• Return every 13 weeks (3 months)
• Up to 2-week grace period acceptable 2
• Efficacy depends on adherence to dosing schedule 1

Self-Administration Option (Subcutaneous Formulation)

Self-administered DMPA-SC should be made available as an additional approach to deliver injectable contraception 2. This represents a 2021 CDC guideline update:

• Same medical eligibility criteria apply as provider-administered DMPA 2
• Available for all eligible users including adolescents 2
• Requires instruction on self-injection technique and sharps disposal 2
• Same reinjection intervals (every 13 weeks, up to 15 weeks) 2
• Should be offered through shared decision-making with access to full range of contraceptive methods 2

Clinical Pearls

• Cost and convenience advantage: Patients using self-administered formulations save approximately $491 on medications and require one fewer monitoring visit per cycle 6
• Estrogen levels: Remain in early-to-mid follicular phase range (mean ~50 pg/mL), but hot flushes are rare and vaginal epithelium remains healthy 4
• Switching from other methods: Ensure continuous contraceptive coverage (e.g., from oral contraceptives, give first injection day after last active tablet or latest on day following final inactive tablet) 1
• No dose adjustment needed for body weight 1

The 2-year duration limit is the most critical counseling point, balanced against the method's high efficacy and convenience for patients who find other options inadequate.